These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 22100006)

  • 41. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Young JG; Subramonian K
    JAMA; 2007 Mar; 297(11):1192-3; author reply 1193. PubMed ID: 17374809
    [No Abstract]   [Full Text] [Related]  

  • 42. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
    Kaplan SA; Schneider T; Foote JE; Guan Z; Carlsson M; Gong J
    BJU Int; 2011 May; 107(9):1432-40. PubMed ID: 20860717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.
    O'Brien BJ; Goeree R; Bernard L; Rosner A; Williamson T
    Clin Ther; 2001 Dec; 23(12):2038-49. PubMed ID: 11813937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ; Kreder KJ; Pleil AM; Burgess SM; Reese PR
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S616-30. PubMed ID: 12516956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
    Armstrong EP; Malone DC; Bui CN
    J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [More quality of life again with tolterodine].
    Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
    Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
    J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model.
    Kobelt G; Jönsson L; Mattiasson A
    Neurourol Urodyn; 1998; 17(6):599-611. PubMed ID: 9829424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of combined behavioral intervention and tolterodine on patient-reported outcomes.
    Wyman JF; Klutke C; Burgio K; Guan Z; Sun F; Berriman S; Bavendam T
    Can J Urol; 2010 Aug; 17(4):5283-90. PubMed ID: 20735908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fesoterodine for the treatment of overactive bladder.
    Tzefos M; Dolder C; Olin JL
    Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.
    Pavesi M; Devlin N; Hakimi Z; Nazir J; Herdman M; Hoyle C; Odeyemi IA
    J Med Econ; 2013 Jul; 16(7):866-76. PubMed ID: 23647446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.